Kanzo
Online ISSN : 1881-3593
Print ISSN : 0451-4203
ISSN-L : 0451-4203
Search
Advanced search
OR
Browse
Search
Volume 49, Issue 4
Displaying 1-6 of 6 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Review Article
Original Articles
  • Pegylated interferon α-2b/ribavirin combination therapy for elderly patients with chronic hepatitis C with high viral load of HCV genotype 1b
    Soo Ryang Kim, Susumu Imoto, Shuichi Fuki, Ke Ih Kim, Miyuki Taniguchi ...
    Article type: Original Article
    2008 Volume 49 Issue 4 Pages 145-152
    Published: 2008
    Released on J-STAGE: April 28, 2008
    DOIhttps://doi.org/10.2957/kanzo.49.145
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The patients (n=75) in this study had chronic hepatitis C with high viral loads of serum HCV-RNA genotype 1b. All the patients received a regimen of pegylated interferon α-2b plus ribavirin (PEG IFN α-2b/RBV) for 48 weeks. Comparative analysis was done by dividing these patients into two groups by age: Elderly group (over 65 years old, 23 patients) and Non-Elderly group (under 65 years old, 52 patients). The sustained viral response (SVR) rate in the Elderly (37.5%, 6/16) was not different significantly from that in the Non-Elderly (50%, 20/40). The response ratio of 2´-5´-oligoadenylate synthetase (2-5AS), the viral dynamics and the rate of discontinuation of therapy were not different between the two groups. Interestingly, however, the mean α-fetoprotein (AFP) values decreased significantly in the Elderly irrespective of SVR or non-SVR (from 10.1±9.55 ng/ml before treatment to 5.18±4.52 ng/ml after treatment, P<0.05), but did not in the Non-Elderly. It was thus suggested that Peg IFN α-2b/RBV would be useful in the prevention of HCC in elderly patients including non-SVR cases.
    View full abstract
    Download PDF (684K)
  • The ultrasonographic hepatic fibrosis scoring system and its implications for esophageal varices in patients with chronic liver diseases
    Tetsuya Nishiura, Hideaki Watanabe, Yoshihiko Kouno, Masahiro Ito, Sei ...
    Article type: Original Article
    2008 Volume 49 Issue 4 Pages 153-158
    Published: 2008
    Released on J-STAGE: April 28, 2008
    DOIhttps://doi.org/10.2957/kanzo.49.153
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Background/Aims: This study was aimed at seeing whether if the ultrasonographic scoring system for edge, surface and texture of the liver (Nishiura et al, 2005) would be useful to predict existence of esophageal varices (EV). Methods: A total of 260 consecutive patients with chronic liver diseases (CLDs) of various etiologies were evaluated by US, blood tests, and upper gastrointestinal endoscope. Results: The US score, splenomegaly, and platelet count were independently associated with the diagnosis of EV. Among these factors, the US score had highest hazard ratio (33.90). A receiver operating characteristic (ROC) curve analysis revealed that US score over 6.0 indicates the existence of EV with sensitivity 94%, specificity 73%, and positive likelihood 3.50. Conclusion: The US scoring is clearly and strongly predictive for EV in patients with CLDs.
    View full abstract
    Download PDF (580K)
Case Reports
  • A case of chronic hepatitis C with sustained virologic response as well as improvement in insulin resistance after antiviral treatment
    Yoshio Sumida, Takako Wada, Naohisa Yoshida, Kyoko Sakai, Kazuyuki Kan ...
    Article type: Case Report
    2008 Volume 49 Issue 4 Pages 159-165
    Published: 2008
    Released on J-STAGE: April 28, 2008
    DOIhttps://doi.org/10.2957/kanzo.49.159
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A 43-year-old man with chronic hepatitis C was referred to our hospital. On admission, his hepatitis C virus (HCV) was of serotype-1 with a viral load at 140 KIU/ml, and a liver biopsy indicated CH (A1/F2). Serum HCV RNA became undetectable at week 4 after starting the combination therapy with pegylated interferon α-2b plus ribavirin, and sustained virologic response was obtained after the standard 48-week treatment. His body weight increased to an extent of obesity after the therapy. Though 75 g-oral glucose tolerance test before and 18 month after the therapy revealed "borderline" in both occasions according to the criteria of the Japan Diabetes Society committee, the areas under the curves of the plasma glucose and immuno-reactive insulin of the post-treatment were significantly smaller than those of the pre-treatment. Thus, this case suggests the direct association of HCV infection with insulin resistance.
    View full abstract
    Download PDF (430K)
  • A case of the drug-induced hepatic injury by Nyoshin-san® and Saffron-K®
    Makoto Irie, Tomoka Fukushima, Teruo Matsumoto, Takashi Tanaka, Kazuhi ...
    Article type: Case Report
    2008 Volume 49 Issue 4 Pages 166-170
    Published: 2008
    Released on J-STAGE: April 28, 2008
    DOIhttps://doi.org/10.2957/kanzo.49.166
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A 55-year-old woman was hospitalized because of general fatigue, jaundice and the elevation of serum hepatic and biliary enzymes. She was suffering from menopausal disorders, and had undergone treatment with oral administration of Nyoshin-san® and the Saffron-K® for 3 months before admission. Liver injury related to Nyoshin-san® and the Saffron-K® was suspected, and the medication was stopped. After cessation of the medication, she recovered from her illness, and the elevated enzymes gradually declined. According to the diagnostic scale for drug-induced hepatic injury at the workshop in Digestive Disease Week-Japan 2004, her liver injury was classified into hepatocellular type and judged "highly possible". These drugs were positive in drug-lymphocyte stimulation test (DLST). Liver biopsy showed the inflammatory infiltrate with eosinophils and slight fibrosis in the portal areas. We hereunder report our experiences on this rare case of drug-induced hepatic injury by Nyoshin-san® and Saffron-K®.
    We reported of the drug-induced hepatic injury by Nyoshin-san and Saffron-K. Our reports experience with a rare case.
    View full abstract
    Download PDF (749K)
Rapid Communication
  • Clinical utility of COBAS AmpliPre/COBAS TaqMan HCV test for evaluating the efficacy of peginterferon plus ribavirin therapy
    Takashi Kumada, Hidenori Toyoda, Seiki Kiriyama, Yasuhiro Sone, Makoto ...
    Article type: Rapid Communication
    2008 Volume 49 Issue 4 Pages 171-173
    Published: 2008
    Released on J-STAGE: April 28, 2008
    DOIhttps://doi.org/10.2957/kanzo.49.171
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We evaluated the performance characteristics of Amplicor HCV v2.0 (Amplicor HCV) and COBAS AmpliPre/COBAS TaqMan HCV test (TaqMan HCV) for predicting sustained virological response (SVR) at 4, 8, and 12 weeks in patients treated with peginterferon plus ribavirin therapy. In genotype 1, the percentage of patients having SVR with undetectable HCV RNA by TaqMan HCV at 8 and 12 weeks is higher than that by Amplicor HCV (90.0% and 72.2% vs 84.6% and 60.0%). However, in genotype 2, there was no difference between Amplicor HCV and TaqMan HCV. We believe TaqMan HCV is useful for determining the duration of treatment with peginterferon plus ribavirin therapy, especially in genotype 1.
    View full abstract
    Download PDF (267K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top